1 / 25

The Role of CETP in Reverse Cholesterol Transport: Will Its Inhibition Reverse Atherosclerosis?

The Role of CETP in Reverse Cholesterol Transport: Will Its Inhibition Reverse Atherosclerosis?. What is the likely mechanism by which HDL-C reduces coronary heart disease?. By what mechanism of action are CETP inhibitors (eg, dalcetrapib, anacetrapib) believed to change lipid levels?.

mark-lynch
Download Presentation

The Role of CETP in Reverse Cholesterol Transport: Will Its Inhibition Reverse Atherosclerosis?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Role of CETP in Reverse Cholesterol Transport: Will Its Inhibition Reverse Atherosclerosis?

  2. What is the likely mechanism by which HDL-C reduces coronary heart disease?

  3. By what mechanism of action are CETP inhibitors (eg, dalcetrapib, anacetrapib) believed to change lipid levels?

  4. Infusing HDL Slows Development and Promotes Regression of Atherosclerosis

  5. Reverse Cholesterol Transport

  6. CETP and Reverse Cholesterol Transport

  7. CETP Deficiency: Geneotype and Risk

  8. CETP Inhibition and the Effect on Lipoprotein Levels

  9. Inhibition of CETP: Effect on HDL Function

  10. ILLUMINATE: Torcetrapib in Patients With High Cardiovascular Risk

  11. Differential Effects of CETP Inhibitors on HDL Subtypes

  12. DEFINE: Effect of Anacetrapib on Lipoprotein(a)

  13. TNT: On-Treatment HDL-C Predicts CV Event 5-Year Risk When LDL-C Is < 70 mg/dL

  14. Meta-analysis of Nicotinic Acid Trials

  15. CETP Inhibitors: Past and Present

  16. ILLUMINATE: Protocol-Specified Secondary and Tertiary Outcomes

  17. Comparison of CETP Inhibitors

  18. Dalcetrapib: Effect on CV Events and Total Vessel Area

  19. dal-OUTCOMES: Study Design

  20. REVEAL: Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification

  21. Program Summary

More Related